Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Other Non Operating Income: 2020-2024

Historic Other Non Operating Income for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $7.6 million.

  • Tango Therapeutics' Other Non Operating Income fell 63.96% to $705,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 49.18%. This contributed to the annual value of $7.6 million for FY2024, which is 28.05% up from last year.
  • Tango Therapeutics' Other Non Operating Income amounted to $7.6 million in FY2024, which was up 28.05% from $5.9 million recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' Other Non Operating Income registered a high of $7.6 million during FY2024, and its lowest value of -$248,000 during FY2021.
  • Moreover, its 3-year median value for Other Non Operating Income was $5.9 million (2023), whereas its average is $5.0 million.
  • As far as peak fluctuations go, Tango Therapeutics' Other Non Operating Income tumbled by 306.67% in 2021, and later skyrocketed by 702.02% in 2022.
  • Yearly analysis of 5 years shows Tango Therapeutics' Other Non Operating Income stood at $120,000 in 2020, then crashed by 306.67% to -$248,000 in 2021, then soared by 702.02% to $1.5 million in 2022, then soared by 298.12% to $5.9 million in 2023, then increased by 28.05% to $7.6 million in 2024.